Siriwat AkapiratAnchalee AvihingsanonJintanat AnanworanichAlexandra SchuetzPongrama RamasootaNatthanej LuplertlopKen Ichiro OnoKazuyoshi IkutaPiraporn UtacheeMasanori KameokaPornsawan LeaungwutiwongMahidol UniversityArmed Forces Research Institute of Medical Sciences, ThailandThe HIV Netherlands Australia Thailand Research CollaborationChulalongkorn UniversityTHE THAI RED CROSS AIDS RCH CTRMedical & Biological Laboratories Co, LtdOsaka UniversityThailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections (RCC-ERI)Kobe University2018-10-192018-10-192013-01-01Southeast Asian Journal of Tropical Medicine and Public Health. Vol.44, No.5 (2013), 825-841012515622-s2.0-84893628395https://repository.li.mahidol.ac.th/handle/20.500.14594/32697We conducted this study to determine the clinical variables associated with the production of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form (CRF) 01_AE neutralizing human monoclonal antibodies (NhMAbs) using a hybridoma technique. This cross sectional study was performed in 20 asymptomatic HIV-1-infected Thais. Peripheral blood mononuclear cells (PBMCs) were obtained from each study participant and fused with SPYMEG cells. Culture supernatant collected from growing hybridomas was tested for neutralizing activity against HIV-1 CRF01_AE Env-recombinant viruses. Fifty hybridomas expressing anti-HIV-1 NhMAbs with strong neutralizing activity against at least 1 CRF01_AE Env-recombinant virus were found. A positive association between the numbers of hybridomas produced and the CD4 counts of study participants (p = 0.019) was observed. NhMAb-producing hybridomas with strong neutralizing activity were mostly found in participants diagnosed with HIV-1 infection within the previous 1 year. The HIV-1 viral load was not significantly correlated with the numbers of either established hybridomas or clones expressing anti-HIV-1 NhMAbs with strong neutralizing activity. To our knowledge, this is the first study of NhMAb-producing hybridomas obtained from HIV-1 CRF01_AE-infected populations identified by antibody binding to HIV-1 V3 loop peptide enzyme-linked immunosorbent assay (ELISA) or TRUGENE HIV-1 Genotyping Assay (HIV-1 pol sequence). It provides important criterion to select study participants with high CD4 counts who produce large numbers of hybridoma clones. The results are valuable for further studies related to neutralizing antibodies production and HIV-1 vaccine development.Mahidol UniversityMedicineArticleSCOPUS